Novartis Ag Quick Ratio (NVS) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Novartis Ag  (NYSE: NVS)

Novartis Ag's Quick Ratio

NVS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 0.41 above Novartis Ag average.

Within Major Pharmaceutical Preparations industry 434 other companies have achieved higher Quick Ratio than Novartis Ag in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 2766.

Explain Quick Ratio?
How much Cash & cash equivalents NVS´s has?
What are NVS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVS Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -12.41 % -4.93 % -4.93 % -4.93 % 12.13 %
Y / Y Cash & cash equivalent Change 0.41 % 0.41 % -16.91 % -24.28 % -16.12 %
Quick Ratio MRQ 0.41 0.43 0.25 0.27 0.36
NVS's Total Ranking # 2766 # 0 # # #
Seq. Current Liabilities Change 2.91 % 0 % 0 % -14.88 % 11.7 %
Seq. Cash & cash equivalent Change 0 % 71.78 % -6.81 % -37.28 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 435
Healthcare Sector # 811
Overall Market # 2766


Quick Ratio Statistics
High Average Low
0.52 0.4 0.27
(Dec 31 2023)   (Dec 31 2022)




Financial Statements
Novartis Ag's Current Liabilities $ 28,072 Millions Visit NVS's Balance sheet
Novartis Ag's Cash & cash equivalent $ 11,640 Millions Visit NVS's Balance sheet
Source of NVS's Sales Visit NVS's Sales by Geography


Cumulative Novartis Ag's Quick Ratio

NVS's Quick Ratio for the trailling 12 Months

NVS Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -6.96 % -0.68 % 2.62 % 6.05 % 9.63 %
Y / Y Cash & cash equivalent TTM Growth -8.83 % -13.64 % -17.98 % -20.35 % -20.19 %
Quick Ratio TTM 0.34 0.33 0.32 0.33 0.35
Total Ranking TTM # 3731 # 0 # # #
Seq. Current Liabilities TTM Growth -3.49 % -1.23 % -1.21 % -1.2 % 3.02 %
Seq. Cash & cash equivalent TTM Growth 0.13 % 0.13 % -3.57 % -5.69 % -5.16 %

Quick ratio ranking by company, industry and sector >> Back to NVS Financial Strength Comparisons >> Go to Compare NVS Quick Ratio to its Competitors

On the trailing twelve months basis NVS Cash & cash equivalent improved by 0.41 % in Q4 2025 year on year, while Current Liabilities rose to $28,072 millions, this led to increase in in Novartis Ag's Quick Ratio to 0.34, Quick Ratio remained below NVS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 459 other companies have achieved higher Quick Ratio than Novartis Ag. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 3731.

Explain Quick Ratio?
How much Cash & cash equivalents NVS´s has?
What are NVS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 460
Healthcare Sector # 950
Within the Market # 3731


trailing twelve months Quick Ratio Statistics
High Average Low
0.52 0.39 0.27
(Dec 31 2023)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Akebia Therapeutics Inc   1.13 $ 184.844  Millions$ 162.938  Millions
Rockwell Medical inc   1.13 $ 10.848  Millions$ 9.580  Millions
Nervgen Pharma Corp   1.12 $ 16.905  Millions$ 15.115  Millions
Alkermes Plc   1.08 $ 588.215  Millions$ 543.437  Millions
Kamada Ltd   1.07 $ 75.469  Millions$ 70.636  Millions
Cingulate Inc   1.06 $ 10.953  Millions$ 10.313  Millions
Dar Bioscience Inc   1.04 $ 24.711  Millions$ 23.686  Millions
Ani Pharmaceuticals Inc  1.02 $ 285.585  Millions$ 279.060  Millions
Xeris Biopharma Holdings Inc   1.01 $ 111.042  Millions$ 109.574  Millions
Evotec Se  1.01 $ 360.490  Millions$ 356.680  Millions
Bausch Health Companies Inc   1.01 $ 1,309.000  Millions$ 1,297.000  Millions
Royalty Pharma Plc  1.00 $ 637.496  Millions$ 636.211  Millions
Mannkind Corporation  1.00 $ 171.346  Millions$ 171.031  Millions
Phathom Pharmaceuticals Inc   0.98 $ 129.972  Millions$ 132.044  Millions
Zymeworks Inc   0.97 $ 41.157  Millions$ 42.318  Millions
Elite Pharmaceuticals Inc   0.96 $ 11.407  Millions$ 11.840  Millions
Zomedica Corp   0.95 $ 9.017  Millions$ 9.449  Millions
Ensysce Biosciences Inc   0.94 $ 4.310  Millions$ 4.568  Millions
Organogenesis Holdings Inc   0.94 $ 93.679  Millions$ 100.124  Millions
Abbott Laboratories  0.93 $ 8,939.000  Millions$ 9,587.000  Millions
Beyondspring Inc   0.93 $ 12.561  Millions$ 13.504  Millions
Tg Therapeutics Inc   0.92 $ 141.970  Millions$ 153.760  Millions
Prestige Consumer Healthcare Inc   0.92 $ 97.884  Millions$ 106.623  Millions
Nanobiotix S a   0.92 $ 59.080  Millions$ 64.408  Millions
Collegium Pharmaceutical Inc   0.91 $ 386.679  Millions$ 425.760  Millions
Ironwood Pharmaceuticals inc   0.89 $ 215.456  Millions$ 243.145  Millions
Medicus Pharma Ltd   0.88 $ 8.705  Millions$ 9.938  Millions
Serina Therapeutics Inc   0.86 $ 3.056  Millions$ 3.563  Millions
Nls Pharmaceutics Ltd  0.86 $ 4.402  Millions$ 5.139  Millions
Cormedix Inc   0.85 $ 157.330  Millions$ 184.012  Millions

Date modified: 2026-09-08T15:11:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.